Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.49 |
| ▸ | BCHE | P06276 | 6/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939383 | 0.85 | BACE1 (0.65) | BACE1BCHEF2CTSD | |
| Hydrochloric Acid SCHEMBL3533305 | 0.84 | BACE1 (0.64) | BACE1BCHEF2CTSD | |
| SCHEMBL3511307 | 0.83 | BCHE (0.44) | BACE1BCHEF2CSNK1ESLC6A11 | |
| SCHEMBL3510321 | 0.83 | BCHE (0.44) | BACE1BCHEF2CTSDCSNK1E | |
| SCHEMBL3511401 | 0.82 | BACE1 (0.50) | BACE1BCHEF2CTSDOPRD1 | |
| SCHEMBL3511403 | 0.82 | BACE1 (0.50) | BACE1BCHEF2CTSDOPRD1 | |
| SCHEMBL6892858 | 0.80 | CYP1A2 (0.53) | BCHE | |
| SCHEMBL3355705 | 0.80 | CYP1A2 (0.53) | BCHE | |
| SCHEMBL3353939 | 0.79 | BCHE (0.61) | BACE1BCHEF2CSNK1ESLC6A11 | |
| SCHEMBL496172 | 0.79 | BCHE (0.61) | BACE1BCHEF2CSNK1ESLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | BACE1, BACE2, PSEN1 | BACE1 1/4885BCHE 11/4885F2 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.